Science

Apr 3, 2025, 09:13

Myeloma Paper of the Day, April 3rd, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Real-world evaluation of teclistamab for relapsed/refractory myeloma from IMWG finds ORR 67% (55% VGPR or better); 6-month PFS and OS 53% and 73%; patients with prior BCMA had lower ORR (58.3 vs 74.0%) and PFS (6-mo PFS 43% vs. 63%).”

“Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study”

Authors: Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Brian Durie, Saad Usmani, Thomas Martin, Yi Lin et al.

More posts featuring Robert Orlowski.

Brian Durie cancer Carlyn Rose Tan Chiung-Yu Huang IMWG International Myeloma Working Group Larissa Brunaldi multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Rakesh Popat relapsed/refractory myeloma Robert Orlowski RRMM Saad Usmani Sireesha Asoori teclistamab Thomas Martin Yi Lin

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book